CymitQuimica logo
Angiogénesis

Angiogénesis

Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.

Subcategorías de "Angiogénesis"

Mostrar 6 subcategorías más

Se han encontrado 2264 productos de "Angiogénesis"

Ordenar por

Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
productos por página.
  • CAY10781

    CAS:
    CAY10781 inhibits NRP-1/VEGF-A binding by 43% at 12.5μM and blocks VEGFR2 phosphorylation in CAD cells.
    Fórmula:C11H9N3O3
    Pureza:99.49%
    Forma y color:Solid
    Peso molecular:231.21

    Ref: TM-T37424

    2mg
    39,00€
    5mg
    54,00€
    10mg
    77,00€
    25mg
    124,00€
    50mg
    172,00€
    100mg
    316,00€
    200mg
    442,00€
    1mL*10mM (DMSO)
    79,00€
  • PROTAC Her3-binding moiety 2

    CAS:
    PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.
    Fórmula:C25H25N7O2
    Forma y color:Solid
    Peso molecular:455.51

    Ref: TM-T212415

    10mg
    A consultar
    50mg
    A consultar
  • VEGFR-2-IN-52

    CAS:
    VEGFR-2-IN-52 (compound 14d) serves as a powerful inhibitor of VEGFR-2, exhibiting an IC 50 of 191.1 nM. It effectively reduces the protein expression levels of p-VEGFR-2, MMP9, p-ERK1/2, and p-MEK1. In addition, VEGFR-2-IN-52 demonstrates cytotoxic properties by inducing apoptosis and arresting the cell cycle at the G0/G1 phase, and it enhances the levels of ROS.
    Fórmula:C20H25ClN4O2S
    Forma y color:Solid
    Peso molecular:420.96

    Ref: TM-T89976

    10mg
    A consultar
    50mg
    A consultar
  • EGFR-IN-35

    CAS:
    EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.
    Fórmula:C25H24ClN7O2
    Forma y color:Solid
    Peso molecular:489.96

    Ref: TM-T63282

    25mg
    1.369,00€
    50mg
    1.783,00€
    100mg
    2.250,00€
  • Tyk2-IN-10

    CAS:
    Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.
    Fórmula:C25H27N5O3
    Forma y color:Solid
    Peso molecular:445.51

    Ref: TM-T89889

    10mg
    A consultar
    50mg
    A consultar
  • VEGFR-2-IN-12


    VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.
    Fórmula:C22H24N6O3S
    Forma y color:Solid
    Peso molecular:452.53

    Ref: TM-T62763

    25mg
    1.369,00€
    50mg
    1.783,00€
    100mg
    2.250,00€
  • EGFR-IN-45


    EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.
    Fórmula:C28H23N7O
    Forma y color:Solid
    Peso molecular:473.53

    Ref: TM-T63070

    25mg
    1.369,00€
    50mg
    1.783,00€
    100mg
    2.250,00€
  • FLT3/TrKA-IN-1


    FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.
    Fórmula:C28H30N4O2
    Forma y color:Solid
    Peso molecular:454.56

    Ref: TM-T62801

    25mg
    1.369,00€
    50mg
    1.783,00€
    100mg
    2.250,00€
  • DDO-02267

    CAS:
    DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.
    Fórmula:C18H12N2O7S
    Forma y color:Solid
    Peso molecular:400.362

    Ref: TM-T204967

    10mg
    A consultar
    50mg
    A consultar
  • FGFR-IN-5

    CAS:
    FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.
    Fórmula:C25H22N6O3
    Forma y color:Solid
    Peso molecular:454.48

    Ref: TM-T62794

    25mg
    1.927,00€
    50mg
    2.507,00€
    100mg
    3.168,00€
  • EGFR/HER2-IN-8


    EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.
    Fórmula:C16H16N4O2S
    Forma y color:Solid
    Peso molecular:328.39

    Ref: TM-T60938

    25mg
    1.444,00€
    50mg
    1.882,00€
    100mg
    2.375,00€
  • VEGFR-2-IN-25

    CAS:
    VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).
    Fórmula:C24H22N6O2
    Forma y color:Solid
    Peso molecular:426.47

    Ref: TM-T62314

    25mg
    1.369,00€
    50mg
    1.783,00€
    100mg
    2.250,00€
  • VEGFR-2-IN-14


    VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.
    Fórmula:C24H23N3O3S
    Forma y color:Solid
    Peso molecular:433.52

    Ref: TM-T62439

    25mg
    1.369,00€
    50mg
    1.783,00€
    100mg
    2.250,00€
  • BTK-IN-10

    CAS:
    BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).
    Fórmula:C25H24F2N4O2
    Forma y color:Solid
    Peso molecular:450.48

    Ref: TM-T62716

    25mg
    1.369,00€
    50mg
    1.783,00€
    100mg
    2.250,00€
  • AZD0424

    CAS:
    AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.
    Fórmula:C25H29ClN6O5
    Pureza:98%
    Forma y color:Solid
    Peso molecular:528.99

    Ref: TM-T14370

    25mg
    2.583,00€
    50mg
    3.402,00€
    100mg
    4.680,00€
  • MTX-216

    CAS:
    MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.
    Fórmula:C22H14Cl2FN5O2S
    Forma y color:Solid
    Peso molecular:502.348

    Ref: TM-T206251

    10mg
    A consultar
    50mg
    A consultar
  • EGFR-IN-146

    CAS:
    EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.
    Fórmula:C20H16N4
    Forma y color:Solid
    Peso molecular:312.368

    Ref: TM-T206146

    10mg
    A consultar
    50mg
    A consultar
  • Multi-kinase inhibitor 3

    CAS:
    Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.
    Fórmula:C26H26N6O2
    Forma y color:Solid
    Peso molecular:454.52

    Ref: TM-T200518

    25mg
    1.444,00€
    50mg
    1.882,00€
    100mg
    2.375,00€
  • Tyrphostin 63

    CAS:
    Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.
    Fórmula:C10H8N2O
    Forma y color:Solid
    Peso molecular:172.183

    Ref: TM-T204167

    10mg
    A consultar
    50mg
    A consultar
  • Lomonitinib

    CAS:

    Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.

    Fórmula:C27H24N4O2
    Forma y color:Solid
    Peso molecular:436.505

    Ref: TM-T205470

    10mg
    A consultar
    50mg
    A consultar